← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
Deanxit tinnitus add-on study
Also known as: Deanxit, Deanxit and Rivotril tinnitus study
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 4
Status
Completed
Target Gene
—
Route / Mode
Oral
Confidence
87%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
Belgium
Population
adult, tinnitus
Trial IDs
1
Mechanism
Randomized double-blind crossover study evaluating Deanxit added to Rivotril in patients with tinnitus.
Indications
Notes
Registry-verified historical academic Phase 4 tinnitus study. No current company-sponsored hearing therapeutic program is implied.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...
IDs: NCT00841230
Key Events
2009-07
Clinical Trials (1)
Data Checks
institution-led-studyregistry-only-evidencehistorical-studynot-confirmed-current-product
Related Programs
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
ACOU085 by Acousia Therapeutics
Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2
CIL001 (Paliroden) by Cilcare
Company: Cilcare SAS · Small Molecule · Phase 1/2